Physician
Hematology
Dr. Lubomir Sokol, MD
|
|
Give Review
Lubomir Sokol practices Hematology. He received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Doctor Lubomir Sokol, MD is also published. He has 36 publications published. The lastest publication: "An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.' He is registered with Medicare and accepts Medicare payments.
Publications
- An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's Lymphoma.
- TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic Syndromes.
- J Cutaneous Pathology Cutaneous Gamma-delta (γδ) T-Cell Lymphoma with Central Nervous System (CNS) Involvement: Report of a Rarity with Review of Literature.
- Hope for orphan lymphoproliferative and histiocytic Diseases on the horizon?
- Blastic plasmacytoid dendritic Cell neoplasm: update on molecular biology, diagnosis, and therapy.
- Dendritic Cell and histiocytic neoplasms: biology, diagnosis, and treatment.
- Hereditary and acquired hemophagocytic lymphohistiocytosis.
- Pathogenesis, diagnosis, and management of kikuchi-fujimoto Disease.
- Rosai-dorfman Disease: tumor biology, clinical features, pathology, and treatment.
- Manifestations of gastrointestinal plasmablastic Lymphoma: A case series with literature review.
- What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system Lymphoma?
- Excimer laser in the treatment of mycosis fungoides.
- Primary B-Cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.
- Serum albumin retains independent prognostic significance in diffuse large B-Cell lymphoma in the post-rituximab era.
- Quantitative flow cytometric identification of aberrant T Cell clusters in erythrodermic cutaneous T Cell lymphoma. Implications for staging and prognosis.
- Primary cutaneous plasmablastic Lymphoma in an immunocompetent patient.
- Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal Cells in large granular lymphocyte leuk...
- TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
- Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-Analysis of observational studies.
- Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-Cell lymphoma with CD20 coexpression and relatively indolent clinical course.
- Quality of life outcomes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
- Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with myelodysplastic Syndrome.
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic Syndrome with chromosome 5q deletion.
- miR-21 mediates hematopoietic suppression in MDS by activating TGF-? signaling.
- Optimizing premedications in the prevention of bendamustine infusion-related reactions.
- Primary cutaneous B-Cell lymphomas: recent advances in diagnosis and management.
- B-Cell non-hodgkin lymphoma: targeting in on the future.
- Erythropoietin receptor signaling is membrane raft dependent.
- A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte Leukemia.
- Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte Leukemia associated with imbalanced NK receptor signaling.
- The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic Syndromes.
- Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-Cell lymph...
- Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic Syndrome progenitors.
- Clinicopathologic Characteristics and Outcomes of Histiocytic and Dendritic Cell Neoplasms: The Moffitt Cancer Center Experience Over the Last Twenty Five Years.
- Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
Schools
Charles University Faculty Of Hygiene
Lousiana State University
University Of South Florida
Charles University Of Prague
Czechoslovak Academy Of Sciences
University Of Alabama
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of South Florida
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute -
Tampa General Hospital
Drug Facts
| NPI NUMBER | 1376558957 | |
| NPPES Provider LastName | SOKOL | |
| NPPES Provider FirstName | LUBOMIR | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 277.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 5.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376558957 |
| Last Name Of The Provider | SOKOL |
| First Name Of The Provider | LUBOMIR |
| View All |
Similar Doctors
|
Dr. Michael T. Tees, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Marcie R. Tomblyn, MD |
|
|
Dr. Elizabeth A. Byron, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Geoffrey T. Gibney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kendra L. Sweet, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hatem Soliman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ankita K. Shah, MD |
|
Dr. Lia E. Perez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard D. Hall Jr., MD |
|
|
Dr. Melanie A. Sheen, MD |